BioSpace News Archive

Alpha Teknova, Inc. announced that the Company will report its financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, following the close of market.

Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced it will report its first quarter 2023 financial results and provide an update on the cytisinicline development program on Tuesday, May 9, 2023 at 4:30 PM EDT.

Direct Biologics, LLC announces U.S. Food and Drug Administration (FDA) clearance of the Company’s investigational new drug (IND) application for a Phase 1b/2a clinical trial to evaluate the safety and efficacy of ExoFlo™ for the treatment of medically refractory perianal fistulizing Crohn’s disease (CD).

Avinger, Inc. today announced the company has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for Tigereye ST, its next-generation image-guided chronic total occlusion (CTO) crossing system.

Invea Therapeutics today announced the acceptance of two abstracts for oral presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting.

Establishment Labs Holdings Inc. plans to announce its financial results for the quarter ended March 31, 2023 after the market closes on Monday, May 8, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results.

SANUWAVE, a leading medical technology company focused on the development and commercialization of non-invasive, regenerative medicine solutions, attended the 3rd Annual Leaders in Wound Healing Conference on April 18th and 19th in New Orleans, LA.

Entera Bio Ltd. announced that Steven R. Goldstein, MD, Professor of Obstetrics and Gynecology at New York University School of Medicine and former President of The International Menopause Society, the North American Menopause Society and recipient of the Clarkson Award from NAMS for lifetime achievement in menopause research will be joining its Clinical and Scientific Advisory Board.

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, announced that following its Type A meeting with the FDA, the Company intends to resubmit its New Drug Application for DefenCath by the middle of May.

Arcturus Therapeutics Holdings Inc. (the today announced that it will release its financial results for the quarter ended March 31, 2023 after the market close on Tuesday, May 9 and will also host a conference call and webcast at 4:30 pm.